Literature DB >> 19876582

Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization.

Serge P Marinkovic1, Lisa M Gillen.   

Abstract

INTRODUCTION AND HYPOTHESIS: Multiple sclerosis is a chronic, debilitating, neurological disease with numerous urological manifestations including urinary detrusor overactivity, detrusor sphincter dyssynergia, and urinary retention. Can sacral neuromodulation be successfully implemented for urinary retention in ambulatory women with multiple sclerosis?
METHODS: Between January 2002 and January 2008, we conducted an observational retrospective case-control study where 12 of 14 consecutive, ambulatory women with multiple sclerosis had stage 1/2 sacral neuromodulation performed under general anesthesia for urinary retention.
RESULTS: Twelve of 14 patients (86%) were successfully implanted, with a mean follow-up of 4.32 +/- 1.32 years and mean postvoid residual of 50.5 +/- 21.18 ml. The mean maximum uroflow was 17.7 +/- 7.9 ml/s. Two of the 12 patients (17%) required revisional surgeries for lead migration, and 40% needed battery replacement.
CONCLUSION: Urinary retention in multiple sclerosis female patients can be successfully and safely managed with sacral neuromodulation with few complications with a mean of 4 years follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19876582     DOI: 10.1007/s00192-009-1023-6

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  13 in total

1.  Sacral neuromodulation for urinary retention in a kidney-transplant patient.

Authors:  Ervin Kocjancic; Simone Crivellaro; Michele Favro; Giovanni Ceratti; Giorgio Monesi; Paolo Gontero; Maurizio Sala; Gianluca Giardiello; Bruno Frea
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

2.  Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study.

Authors:  Philip E V van Kerrebroeck; Anco C van Voskuilen; John P F A Heesakkers; August A B Lycklama á Nijholt; Steven Siegel; U Jonas; Clare J Fowler; Magnus Fall; Jerzy B Gajewski; Magdy M Hassouna; Francesco Cappellano; Mostafa M Elhilali; Douglas F Milam; Anurag K Das; H E Dijkema; Ubi van den Hombergh
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

3.  Urinary retention following tension-free vaginal tape successfully treated by sacral neuromodulation.

Authors:  Rony A Adam
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-01-12

Review 4.  Multiple sclerosis and the urologist.

Authors:  S E Litwiller; E M Frohman; P E Zimmern
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

Review 5.  Diagnosis and management of multiple sclerosis.

Authors:  Peter A Calabresi
Journal:  Am Fam Physician       Date:  2004-11-15       Impact factor: 3.292

Review 6.  Sacral nerve stimulation to treat nonobstructive urinary retention in women.

Authors:  Craig V Comiter
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

7.  Urodynamic study of women in urinary retention treated with sacral neuromodulation.

Authors:  Ranan DasGupta; Clare J Fowler
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

8.  Sacral neurostimulation for urinary retention: 10-year experience from one UK centre.

Authors:  Soumendra N Datta; Charlotte Chaliha; Anubha Singh; Gwen Gonzales; Vibhash C Mishra; Rajesh B C Kavia; Neil Kitchen; Clare J Fowler; Sohier Elneil
Journal:  BJU Int       Date:  2007-10-26       Impact factor: 5.588

9.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

10.  Sacral neuromodulation reprogramming: is it an office burden?

Authors:  Frank N Burks; Ananais C Diokno; Michelle J Lajiness; Ibrahim A Ibrahim; Kenneth M Peters
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-04-05
View more
  12 in total

Review 1.  Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.

Authors:  Federica Puccini; Alka Bhide; Suzy Elneil; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2015-07-09       Impact factor: 2.894

Review 2.  The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.

Authors:  A Tubaro; F Puccini; C De Nunzio; G A Digesu; S Elneil; C Gobbi; V Khullar
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

Review 3.  [What is new in symptomatic MS treatment: Part 3-bladder dysfunction].

Authors:  T Henze; W Feneberg; P Flachenecker; D Seidel; H Albrecht; M Starck; S G Meuth
Journal:  Nervenarzt       Date:  2018-02       Impact factor: 1.214

Review 4.  Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines.

Authors:  Shachar Moshe Aharony; Ornella Lam; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2017-03-16       Impact factor: 1.862

Review 5.  Invasive Therapies in Multiple Sclerosis.

Authors:  Cihat Uzunköprü
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

6.  Sacral neuromodulation in patients with multiple sclerosis.

Authors:  Daniele Minardi; Giovanni Muzzonigro
Journal:  World J Urol       Date:  2011-03-15       Impact factor: 4.226

Review 7.  Management of neurogenic bladder in patients with multiple sclerosis.

Authors:  Véronique Phé; Emmanuel Chartier-Kastler; Jalesh N Panicker
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

Review 8.  Neuromodulation in neurogenic bladder.

Authors:  Melissa T Sanford; Anne M Suskind
Journal:  Transl Androl Urol       Date:  2016-02

9.  Neuromodulation for functional bladder disorders in patients with multiple sclerosis.

Authors:  Mohammad Sajjad Rahnama'i
Journal:  Mult Scler       Date:  2019-12-09       Impact factor: 6.312

10.  Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series.

Authors:  Daniel S Engeler; Daniel Meyer; Dominik Abt; Stefanie Müller; Hans-Peter Schmid
Journal:  BMC Urol       Date:  2015-10-23       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.